15 results on '"Vinatier D"'
Search Results
2. The use of intravenous nitroglycerin for cervico-uterine relaxation: a review of the literature
- Author
-
Dufour, P., Vinatier, D., and Puech, F.
- Published
- 1997
- Full Text
- View/download PDF
3. Pregnancy after myocardial infarction and a coronary artery bypass graft
- Author
-
Dufour, P., Berard, J., Vinatier, D., Subtil, D., Guionet, B., Bourzoufi, K., Michon, P., and Puech, F.
- Published
- 1997
- Full Text
- View/download PDF
4. Direct profiling and MALDI Imaging in clinical proteomic
- Author
-
Stauber, J., Lemaire, R., Wisztorski, M., Ait-Menguellet, S., P. Lucot, J., Vinatier, D., Desmons, A., Deschamps, M., Proess, G., Rudlof, I., Salzet, M., Fournier, I., Neuroimmunologie des annélides (NA), Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), Hôpital Jeanne de Flandres, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Eurogentec S.A. [Seraing, Belgique], ACI, CNRS DPI, Genopole Lille, and Salzet, Michel
- Subjects
[SDV.IB] Life Sciences [q-bio]/Bioengineering ,[CHIM.ANAL] Chemical Sciences/Analytical chemistry ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Maldi Imaging ,[CHIM.ANAL]Chemical Sciences/Analytical chemistry ,[SDV.BBM] Life Sciences [q-bio]/Biochemistry, Molecular Biology ,[SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,[SDV.IB]Life Sciences [q-bio]/Bioengineering ,Mass Spectrometry ,Cancer - Abstract
International audience; MALDI direct analysis and MALDI imaging of tissues have shown to be a very powerful tool by localizing molecules in tissue and by avoiding extraction, pre-purification, separation. Nevertheless, this new method requires new developments to increase sensitivity and specificity. We propose here a new concept and evolutions of each step of MALDI Imaging analysis. New matrices called Ionic matrices were synthesized to be especially well adapted for a good crystallization, sensitivity and resolution compared to the classical matrices. Moreover, for tissue kept in hospital libraries, FFPE tissues we developed a new strategy of in situ tissue enzymatic digestion was developed in combination with automatic microspotting MALDI Imaging. In order to add a dimension of specificity to imaging by MS, we have developed specific imaging using designed probes directed against specific targets with mass spectrometry detection. This strategy has been developed for different class of biomolecules with a specific highlight, to mRNA and peptides/proteins. This concept is based of indirect detection of specific targeted molecule using a photocleavable tagged probe. The introduction of the specific imaging give another dimension by targeting specific disease-marker-gene RNA transcripts, following their expression within tissues and then confirming their translation by targeting their specific proteinproducts or metabolites
- Published
- 2006
5. Immunological aspects of endometriosis
- Author
-
Vinatier, D, primary
- Published
- 1996
- Full Text
- View/download PDF
6. Decreased expression of eosinophil peroxidase and major basic protein messenger RNAs during eosinophil maturation
- Author
-
Gruart, V, primary, Truong, MJ, additional, Plumas, J, additional, Zandecki, M, additional, Kusnierz, JP, additional, Prin, L, additional, Vinatier, D, additional, Capron, A, additional, and Capron, M, additional
- Published
- 1992
- Full Text
- View/download PDF
7. Anti-P30 IgA antibodies as prenatal markers of congenital toxoplasma infection
- Author
-
DECOSTER, A, primary, DARCY, F, additional, CARON, A, additional, VINATIER, D, additional, DE L'AULNOIT, D HOUZE, additional, VITTU, G, additional, NIEL, G, additional, HEYER, F, additional, LECOLIER, B, additional, DELCROIX, M, additional, MONNIER, J C, additional, DUHAMEL, M, additional, and CAPRON, A, additional
- Published
- 1992
- Full Text
- View/download PDF
8. MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers
- Author
-
El Ayed M, Bonnel D, Longuespée R, Castelier C, Franck J, Vergara D, Desmons A, Tasiemski A, Kenani A, Vinatier D, Day R, Fournier I, Michel Salzet, El Ayed, M, Bonnel, D, Longuespée, R, Castelier, C, Franck, J, Vergara, D, Desmons, A, Tasiemski, A, Kenani, A, Vinatier, D, Day, R, Fournier, I, and Salzet, M.
9. Epithelial-mesenchymal transition in ovarian cancer
- Author
-
Isabelle Fournier, Pierre Collinet, Benjamin Merlot, Jean-Philippe Lucot, Michel Salzet, Denis Vinatier, Daniele Vergara, Vergara, D, Merlot, B, Lucot, Jp, Collinet, P, Vinatier, D, Fournier, I, and Salzet, M.
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Bone Morphogenetic Protein 4 ,Biology ,Metastasis ,Mesoderm ,Epidermal growth factor ,Transforming Growth Factor beta ,Internal medicine ,medicine ,Humans ,Growth factor receptor inhibitor ,Epithelial–mesenchymal transition ,Neoplasm Metastasis ,Ovarian Neoplasms ,Endothelin-1 ,Epidermal Growth Factor ,Hepatocyte Growth Factor ,Cancer ,Cell Differentiation ,Epithelial Cells ,medicine.disease ,Cadherins ,Cancer research ,Hepatocyte growth factor ,Female ,Ovarian cancer ,Transforming growth factor ,medicine.drug - Abstract
Ovarian cancer is a highly metastatic disease and the leading cause of death from gynecologic malignancy. Hence, and understanding of the molecular changes associated with ovarian cancer metastasis could lead to the identification of targets for novel therapeutic interventions. The conversion of an epithelial cell to a mesenchymal cell plays a key role both in the embryonic development and cancer invasion and metastasis. Cells undergoing epithelial–mesenchymal transition (EMT) lose their epithelial morphology, reorganize their cytoskeleton and acquire a motile phenotype through the up- and down-regulation of several molecules including tight and adherent junctions proteins and mesenchymal markers. EMT is believed to be governed by signals from the neoplastic microenvironment including a variety of cytokines and growth factors. In ovarian cancer EMT is induced by transforming growth factor-β (TGF-β), epidermal growth factor (EGF), hepatocyte growth factor (HGF) and endothelin-1 (ET-1). Alterations in these cellular pathways candidate them as useful target for ovarian cancer treatment.
- Published
- 2009
10. In vivo Real-Time Mass Spectrometry for Guided Surgery Application.
- Author
-
Fatou B, Saudemont P, Leblanc E, Vinatier D, Mesdag V, Wisztorski M, Focsa C, Salzet M, Ziskind M, and Fournier I
- Subjects
- Female, Humans, Laser Therapy instrumentation, Male, Skin pathology, Mass Spectrometry instrumentation, Minimally Invasive Surgical Procedures instrumentation
- Abstract
Here we describe a new instrument (SpiderMass) designed for in vivo and real-time analysis. In this instrument ion production is performed remotely from the MS instrument and the generated ions are transported in real-time to the MS analyzer. Ion production is promoted by Resonant Infrared Laser Ablation (RIR-LA) based on the highly effective excitation of O-H bonds in water molecules naturally present in most biological samples. The retrieved molecular patterns are specific to the cell phenotypes and benign versus cancer regions of patient biopsies can be easily differentiated. We also demonstrate by analysis of human skin that SpiderMass can be used under in vivo conditions with minimal damage and pain. Furthermore SpiderMass can also be used for real-time drug metabolism and pharmacokinetic (DMPK) analysis or food safety topics. SpiderMass is thus the first MS based system designed for in vivo real-time analysis under minimally invasive conditions.
- Published
- 2016
- Full Text
- View/download PDF
11. Implications of a two-step procedure in surgical management of patients with early-stage endometrioid endometrial cancer.
- Author
-
Arsène E, Bleu G, Merlot B, Boulanger L, Vinatier D, Kerdraon O, and Collinet P
- Subjects
- Aged, Carcinoma, Endometrioid epidemiology, Carcinoma, Endometrioid pathology, Endometrial Neoplasms epidemiology, Endometrial Neoplasms pathology, Female, Humans, Lymph Node Excision standards, Lymph Node Excision statistics & numerical data, Middle Aged, Morbidity, Neoplasm Staging standards, Pelvis, Postoperative Complications epidemiology, Prognosis, Reoperation statistics & numerical data, Retrospective Studies, Carcinoma, Endometrioid surgery, Endometrial Neoplasms surgery, Hysterectomy methods, Hysterectomy statistics & numerical data, Lymph Node Excision methods, Salpingectomy methods, Salpingectomy statistics & numerical data
- Abstract
Objective: Since European Society for Medical Oncology (ESMO) recommendations and French guidelines, pelvic lymphadenectomy should not be systematically performed for women with early-stage endometrioid endometrial cancer (EEC) preoperatively assessed at presumed low- or intermediate-risk. The aim of our study was to evaluate the change of our surgical practices after ESMO recommendations, and to evaluate the rate and morbidity of second surgical procedure in case of understaging after the first surgery., Methods: This retrospective single-center study included women with EEC preoperatively assessed at presumed low- or intermediate-risk who had surgery between 2006 and 2013. Two periods were defined the times before and after ESMO recommendations. Demographics characteristics, surgical management, operative morbidity, and rate of understaging were compared. The rate of second surgical procedure required for lymph node resection during the second period and its morbidity were also studied., Results: Sixty-one and sixty-two patients were operated for EEC preoperatively assessed at presumed low-or intermediate-risk before and after ESMO recommendations, respectively. Although immediate pelvic lymphadenectomy was performed more frequently during the first period than the second period (88.5% vs. 19.4%; p<0.001), the rate of postoperative risk-elevating or upstaging were comparable between the two periods (31.1% vs. 27.4%; p=0.71). Among the patients requiring second surgical procedure during the second period (21.0%), 30.8% did not undergo the second surgery due to their comorbidity or old age. For the patients who underwent second surgical procedure, mean operative time of the second procedure was 246.1±117.8 minutes. Third operation was required in 33.3% of them because of postoperative complications., Conclusion: Since ESMO recommendations, second surgical procedure for lymph node resection is often required for women with EEC presumed at low- or intermediate-risk. This reoperation is not always performed due to age/comorbidity of the patients, and presents a significant morbidity.
- Published
- 2015
- Full Text
- View/download PDF
12. Detection of non-Hodgkin's lymphoma in ovarian cortex pieces during the process of cryopreservation.
- Author
-
Gronier H, Terriou L, Robin G, Wacrenier A, Leroy-Martin B, Lefebvre C, Vinatier D, Morschhauser F, and Decanter C
- Subjects
- Adult, Cryopreservation, Female, Humans, Fertility Preservation, Lymphoma, B-Cell pathology, Mediastinal Neoplasms pathology, Ovary pathology
- Published
- 2014
- Full Text
- View/download PDF
13. Spectroimmunohistochemistry: a novel form of MALDI mass spectrometry imaging coupled to immunohistochemistry for tracking antibodies.
- Author
-
Longuespée R, Boyon C, Desmons A, Kerdraon O, Leblanc E, Farré I, Vinatier D, Day R, Fournier I, and Salzet M
- Subjects
- Antibodies, Neoplasm immunology, Antigen-Antibody Complex chemistry, Antigens, Neoplasm immunology, Carcinoma, Endometrioid immunology, Carcinoma, Endometrioid pathology, Cystadenoma, Serous immunology, Cystadenoma, Serous pathology, Female, Humans, Immunohistochemistry instrumentation, Neoplasm Staging, Ovarian Neoplasms immunology, Ovarian Neoplasms pathology, Peptides analysis, Proteolysis, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization instrumentation, Trypsin chemistry, Antibodies, Neoplasm analysis, Carcinoma, Endometrioid diagnosis, Cystadenoma, Serous diagnosis, Immunohistochemistry methods, Ovarian Neoplasms diagnosis, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization methods
- Abstract
MALDI mass spectrometry imaging (MALDI-MSI) is currently used for clinical applications, such as biomarker identification, particularly for the study of solid tumors. The ability to map specific compounds that have been determined to be biomarkers and therapeutic targets is relevant for the evaluation of the efficacy of targeted therapies. This article describes a new method called Spectro-ImmunoHistoChemistry (SIHC), which combines the use of specific antibodies against markers and mass spectrometric imaging in the MS/MS mode. SIHC is based on direct primary antibody-antigen recognition, trypsin digestion of the antibody overlaying the markers of interest in the tissue section, and MALDI-MSI of the tryptic peptides generated from the antibody. This approach has both clinical and pharmacological applications. First, it can be used as a cross-validation method to monitor the presence specifically of a marker in a tissue section. Second, SIHC could potentially be used as a novel technology for tracking specific antibodies after in vivo injection for anti-cancer treatments. Additionally, SIHC could enable novel clinical applications of MSI, such as monitoring the efficacy of cytotoxic antibody treatments.
- Published
- 2014
- Full Text
- View/download PDF
14. MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers.
- Author
-
El Ayed M, Bonnel D, Longuespée R, Castelier C, Franck J, Vergara D, Desmons A, Tasiemski A, Kenani A, Vinatier D, Day R, Fournier I, and Salzet M
- Subjects
- Adenocarcinoma, Mucinous, Amino Acid Sequence, Biomarkers, Tumor chemistry, Female, Gene Expression Regulation, Neoplastic, Humans, Molecular Sequence Data, Molecular Weight, Nanotechnology, Neoplasm Proteins chemistry, Neoplasm Proteins metabolism, Neoplasm Staging, Ovarian Neoplasms genetics, Ovarian Neoplasms pathology, Principal Component Analysis, Reproducibility of Results, Biomarkers, Tumor metabolism, Ovarian Neoplasms diagnosis, Ovarian Neoplasms metabolism, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization methods
- Abstract
Background: Among biomarkers, cancer-antigen 125 (CA-125) is the most studied. We propose an analytical tool to track ovarian carcinoma biomarkers, that is, the MALDI mass spectrometry imaging., Material/methods: Ovarian carcinomas and benign ovaries were directly analyzed by MALDI-TOF-MS. After automatic profiling and mass spectrometry imaging analyses, hierarchical clustering based on principal component analysis in nonsupervised mode was carried out. On the same samples, preparations were performed to investigate peptides, then proteins, followed by high mass proteins, in an automatic profiling to specific signatures for diagnosis. Using tissue bottom-up strategy on tissue digestion, and mass spectrometry imaging after by shotgun sequencing by nalano-LC-IT-MS in MS/MS mode from washing samples from on tissue digested peptides, several biomarkers were found., Results: A list of specific biomarkers from the ovarian carcinoma regions was obtained and classified as proteins associated with cell proliferation, involved in immune response modulation, signaling to the cytoskeleton, and tumor progression. These specific biomarkers were then validated by immunocytochemistry using Tag-mass technology, cell biology, Western blot, and by PCR (using SKOV-3 ovarian epithelial cancer cells). A link between the immune regulation (innate immunity, tolerance) and virus cause is also discussed., Conclusions: From the biomarkers identified, proteins involved in immune response modulation and cell proliferation have been pointed out in this study. Two new markers have been identified using such a strategy, that is, fragment C-terminal of the PSME1 (Reg-Alpha) and mucin-9.
- Published
- 2010
15. MALDI imaging mass spectrometry: state of the art technology in clinical proteomics.
- Author
-
Franck J, Arafah K, Elayed M, Bonnel D, Vergara D, Jacquet A, Vinatier D, Wisztorski M, Day R, Fournier I, and Salzet M
- Subjects
- Animals, Diagnostic Techniques and Procedures, Disease, Humans, Proteins analysis, Clinical Medicine methods, Proteomics methods, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization methods
- Abstract
A decade after its inception, MALDI imaging mass spectrometry has become a unique technique in the proteomics arsenal for biomarker hunting in a variety of diseases. At this stage of development, it is important to ask whether we can consider this technique to be sufficiently developed for routine use in a clinical setting or an indispensable technology used in translational research. In this report, we consider the contributions of MALDI imaging mass spectrometry and profiling technologies to clinical studies. In addition, we outline new directions that are required to align these technologies with the objectives of clinical proteomics, including: 1) diagnosis based on profile signatures that complement histopathology, 2) early detection of disease, 3) selection of therapeutic combinations based on the individual patient's entire disease-specific protein network, 4) real time assessment of therapeutic efficacy and toxicity, 5) rational redirection of therapy based on changes in the diseased protein network that are associated with drug resistance, and 6) combinatorial therapy in which the signaling pathway itself is viewed as the target rather than any single "node" in the pathway.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.